A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
מצבים רפואיים
Solid Tumor, Adult · Colorectal Cancer · Non-Small Cell Lung · NSCLC (Non-small Cell Lung Cancer) · Cancer · Colon Cancer · Rectal Cancer · Lung Cancer · CRC · Head and Neck Squamous Cell Cancer · HNSCC · Renal Cell Carcinoma · RCC · Kidney Cancer · Triple Negative Breast Cancer · TNBC · Colorectal Adenocarcinoma
סיכום בשפה פשוטהבעזרת בינה מלאכותית
הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.
מיקומים
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Contact: Principal Investigator (Matthew Ulrickson, MD)UCSD Moores Cancer Center, La Jolla, California, United States
Contact: Principal Investigator (Rebecca Shatsky, MD)UCLA Medical Center, Los Angeles, California, United States
Contact: Principal Investigator (Deborah Wong, MD)Mayo Clinic, Jacksonville, Florida, United States
Contact: Principal Investigator (Yanyan Lou, MD)Moffitt Cancer Center, Tampa, Florida, United States
Contact: Principal Investigator (Kedar Kirtane, MD)Mayo Clinic, Rochester, Minnesota, United States
Contact: Principal Investigator (Harry E. Fuentes Bayne, MD)Washington University, St Louis, Missouri, United States
Contact: Principal Investigator (Patrick Grierson, M.D., Ph.D.)NYU Langone Health, New York, New York, United States
Contact: Principal Investigator (Salman Punekar, MD)The Ohio State University, Columbus, Ohio, United States
Contact: Principal Investigator (Kai He, MD, PhD)Fred Hutch Cancer Center, Seattle, Washington, United States
Contact: Principal Investigator (Jennifer Specht, MD)
מובילי המחקר
John Welch, MD, PhD
Study Director
A2 Biotherapeutics